Rapport Therapeutics: director Paul Steven M bought 35,714 shares

What happened

• Paul Steven M, a director of Rapport Therapeutics, acquired 35,714 shares in an open-market or private purchase (code P) on Oct 22, 2026. The Form 4 reports a weighted average price of $27.28 and a total purchase value of $974,278.

Key details

• Transaction date and price: Oct 22, 2026; weighted average price $27.28 (shares purchased in multiple transactions at prices ranging from $26.87 to $27.84) (see footnote F1).
• Transaction type: Open market or private purchase (P).
• Shares owned after the transaction: not reported in the Form 4.
• Footnotes: F1 notes the weighted average price and the per-share price range and offers to provide per-transaction details on request; F2 states the shares are held by Paul Capital Strategy III Fund LLC and the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
• Filing timeliness: the Form 4 was filed on Oct 22, 2026, the same date reported.

Why it may matter

• This filing records a purchase (code P); it does not report an option exercise, gift, or other derivative transaction.
• A filing does not show why the insider traded or why the company acted.